Perioperative immunotherapy plus chemotherapy for resectable throat cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding camrelizumab (an immune system drug) to chemotherapy before and around surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma (ESCC). If you are eligible, treatment is given around the time of planned surgery to remove the tumor and lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 80 and can be male or female.
- Your diagnosis is ESCC confirmed by tissue or cell testing, not small-cell or other cancer types.
- Your cancer stage is T1b-2 with lymph nodes, or T3-4a with lymph nodes, and it has not spread to distant organs (M0).
- You have a surgery plan for curative ESCC removal with reconstruction and at least complete 2-field lymph node dissection.
- You must be well enough for treatment: ECOG 0–1, expected survival at least 12 weeks, and organ blood tests fall within set limits (counts, liver, kidney, and clotting).
- You must be able to provide tumor tissue for PD-L1 testing and be willing to sign consent and attend follow-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.